These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26671977)

  • 1. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
    Bikas A; Kundra P; Desale S; Mete M; O'Keefe K; Clark BG; Wray L; Gandhi R; Barett C; Jelinek JS; Wexler JA; Wartofsky L; Burman KD
    Eur J Endocrinol; 2016 Mar; 174(3):373-80. PubMed ID: 26671977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
    Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
    Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
    Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
    Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.
    Díez JJ; Iglesias P; Alonso T; Grande E
    Endocrine; 2015 Mar; 48(2):582-8. PubMed ID: 25030550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.
    Pasqualetti G; Ricci S; Boni G; Tognini S; Polini A; Mariani G; Ferdeghini M; Monzani F
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):171-6. PubMed ID: 22533521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
    Carr LL; Mankoff DA; Goulart BH; Eaton KD; Capell PT; Kell EM; Bauman JE; Martins RG
    Clin Cancer Res; 2010 Nov; 16(21):5260-8. PubMed ID: 20847059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
    Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motesanib diphosphate in progressive differentiated thyroid cancer.
    Sherman SI; Wirth LJ; Droz JP; Hofmann M; Bastholt L; Martins RG; Licitra L; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Schlumberger MJ;
    N Engl J Med; 2008 Jul; 359(1):31-42. PubMed ID: 18596272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.
    Hayes DN; Lucas AS; Tanvetyanon T; Krzyzanowska MK; Chung CH; Murphy BA; Gilbert J; Mehra R; Moore DT; Sheikh A; Hoskins J; Hayward MC; Zhao N; O'Connor W; Weck KE; Cohen RB; Cohen EE
    Clin Cancer Res; 2012 Apr; 18(7):2056-65. PubMed ID: 22241789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
    Dadu R; Shah K; Busaidy NL; Waguespack SG; Habra MA; Ying AK; Hu MI; Bassett R; Jimenez C; Sherman SI; Cabanillas ME
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E77-81. PubMed ID: 25353071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
    Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
    Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
    Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
    Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib therapy in metastatic papillary thyroid cancer.
    Gori S; Foglietta J; Rossi M; Hamzaj A; Stocchi L; Galuppo C; Picece V; Puxeddu E; Furlani L
    Tumori; 2013; 99(6):285e-7e. PubMed ID: 24503805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
    Dawson SJ; Conus NM; Toner GC; Raleigh JM; Hicks RJ; McArthur G; Rischin D
    Anticancer Drugs; 2008 Jun; 19(5):547-52. PubMed ID: 18418222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.